Cue Biopharma, Inc. $CUE Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC lessened its stake in Cue Biopharma, Inc. (NASDAQ:CUE) by 10.3% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 213,828 shares of the company’s stock after selling 24,526 shares during the period. Renaissance Technologies LLC owned 5.43% of Cue Biopharma worth $49,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Cue Biopharma by 730.0% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock worth $57,000 after acquiring an additional 73,000 shares during the period. Squarepoint Ops LLC bought a new position in shares of Cue Biopharma in the third quarter valued at approximately $62,000. Stifel Financial Corp increased its stake in shares of Cue Biopharma by 25.4% during the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock valued at $75,000 after acquiring an additional 50,000 shares during the period. Texas Capital Bank Wealth Management Services Inc increased its stake in shares of Cue Biopharma by 1,231.2% during the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock valued at $135,000 after acquiring an additional 407,568 shares during the period. Finally, Boothbay Fund Management LLC raised its holdings in Cue Biopharma by 15.3% during the fourth quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock worth $215,000 after purchasing an additional 93,333 shares in the last quarter. Institutional investors and hedge funds own 35.04% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Cue Biopharma in a research report on Thursday, August 13th. Wall Street Zen cut Cue Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 15th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Cue Biopharma presently has an average rating of “Sell”.

Insider Buying and Selling

In other news, CEO Shao-Lee Lin sold 40,000 shares of Cue Biopharma stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $27.10, for a total value of $1,084,000.00. Following the transaction, the chief executive officer directly owned 724,253 shares of the company’s stock, valued at $19,627,256.30. This trade represents a 5.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Michael Vincent Meluzio sold 5,628 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $30.09, for a total transaction of $169,346.52. Following the sale, the vice president owned 48,961 shares in the company, valued at $1,473,236.49. This represents a 10.31% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 72,715 shares of company stock valued at $2,041,555. 14.56% of the stock is owned by corporate insiders.

Cue Biopharma Stock Performance

NASDAQ CUE opened at $23.98 on Friday. The stock has a market capitalization of $174.09 million, a P/E ratio of -0.89 and a beta of 2.47. Cue Biopharma, Inc. has a 1 year low of $4.97 and a 1 year high of $45.50. The business’s fifty day moving average is $29.28 and its two-hundred day moving average is $136.71.

Cue Biopharma (NASDAQ:CUE) last released its quarterly earnings data on Friday, August 14th. The company reported ($24.14) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($22.45). The company had revenue of $7.88 million for the quarter, compared to the consensus estimate of $3.00 million. Cue Biopharma had a negative return on equity of 620.06% and a negative net margin of 435.83%.

Cue Biopharma Profile

Cue Biopharma is a clinical?stage biotechnology company focused on the development of next?generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen?specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early?stage clinical studies.